QBD-DRIVEN DESIGN AND PHARMACOKINETIC PROFILING OF REMOGLIFLOZIN ETABONATE SUSTAINED-RELEASE MATRIX TABLETS FOR DIABETES MANAGEMENT

Authors

  • MUSKAN A. KHAN Department of Pharmaceutics, Pravara Rural Education Society’s, College of Pharmacy (For Women), Chincholi-422102, Nashik, Maharashtra, India. Department of Pharmaceutics, JMCT Institute of Pharmacy, Nashik-422214, Maharashtra, India https://orcid.org/0009-0002-6277-7563
  • SACHIN B. SOMWANSHI Department of Pharmaceutics, Pravara Rural Education Society’s, College of Pharmacy (For Women), Chincholi-422102, Nashik, Maharashtra, India https://orcid.org/0000-0002-9131-6910
  • KAVERI T. VADITAKE Department of Pharmaceutical Chemistry, Pravara Rural Education Society’s, College of Pharmacy (For Women), Chincholi-422102, Nashik, Maharashtra, India https://orcid.org/0000-0002-9182-1159
  • KIRAN B. KOTADE Department of Pharmacology, Pravara Rural Education Society’s, College of Pharmacy (For Women), Chincholi-422102, Nashik, Maharashtra, India https://orcid.org/0000-0002-7066-2646

DOI:

https://doi.org/10.22159/ijap.2026v18i1.56445

Keywords:

Remogliflozin etabonate, Sustained-release matrix tablet, Quality by design, Pharmacokinetics, Eudragit L100, MCC

Abstract

Objective: With an emphasis on type 2 diabetes treatment, this work applied a QbD-based framework to design and optimize sustained-release Remogliflozin etabonate tablets, intending to enhance therapeutic effectiveness and patient adherence for type 2 diabetes management.

Methods: The study implemented a full factorial design to explore how Eudragit L100 and microcrystalline cellulose influence drug release and tablet hardness. The formulations were developed via direct compression and subjected to comprehensive evaluation, including pre-and post-compression properties, dissolution kinetics, compatibility, stability, and in vivo pharmacokinetic behavior in Wistar rats. Statistical analysis and formulation optimization were executed using Design Expert® software.

Results: All formulations met pharmacopoeial quality standards. The optimized formulation (F5) demonstrated 99.26±0.65 % cumulative drug release within 10 h, with release kinetics best fitting the Korsmeyer-Peppas model with a correlation coefficient of R² = 0.9976, indicating anomalous diffusion. Pharmacokinetic studies revealed significantly lower Cmax (94.62±4.3 ng/ml vs. 127.51±6.1 ng/ml, p<0.01), prolonged Tmax (5.84±1.28 h vs. 1.99±0.34 h, p<0.001), and enhanced systemic exposure (AUC₀–t: 2176.39±48.13 vs. 1987.96±37.24 ng h/ml, p<0.05; AUC₀–∞: 2598.81±73.42 vs. 2263.35±56.62 ng h/ml, p<0.05). The half-life of the optimized SR-matrix tablets (7.64±0.17 h) was significantly extended compared to the marketed reference tablet (5.93±0.28 h, p<0.05). Accelerated stability testing confirmed consistent physical and chemical attributes over 6 mo.

Conclusion: The QbD-driven approach successfully optimized RE SR-matrix tablets with robust sustained release behavior, improved pharmacokinetic performance, and satisfactory stability. These findings suggest the formulation as a promising strategy for sustained glycemic control and improved patient compliance in type 2 diabetes therapy.

References

1. Sune PR, Jumde KS, Hatwar PR, Bakal RL, Korde AV. Advances in oral controlled release drug delivery systems. GSC Biol Pharm Sci. 2024;29(3):286-97. doi: 10.30574/gscbps.2024.29.3.0475.

2. Bhutani U, Basu T, Majumdar S. Oral drug delivery: conventional to long-acting new-age designs. Eur J Pharm Biopharm. 2021;162:23-42. doi: 10.1016/j.ejpb.2021.02.008, PMID 33631319.

3. Park K. Controlled drug delivery systems: past, forward and future back. J Control Release. 2014 Sep 28;190:3-8. doi: 10.1016/j.jconrel.2014.03.054, PMID 24794901.

4. Ghosh TK, Jasti BR. Theory and practice of contemporary pharmaceutics. In: Akala EO, editor. Oral controlled release solid dosage forms. CRC PRESS; 2005. p. 333-65.

5. Purohita HS, Zhoub D, Yua M, Zaroudic M, Oberoia H, Angelica De L. Proof-of-concept in developing a 45% drug loaded amorphous nanoparticle formulation. J Pharm Sci. 2024;113(4):1007-19. doi: 10.1016/j.xphs.2023.10.012.

6. Adepu S, Ramakrishna S. Controlled drug delivery systems: current status and future directions. Molecules. 2021 Sep 29;26(19):5905. doi: 10.3390/molecules26195905, PMID 34641447.

7. Prajapat P, Agrawal D, Bhaduka G. A brief overview of sustained released drug delivery system. J Appl Pharm Res. 2022;10(3):5-11. doi: 10.18231/j.joapr.2022.10.3.5.11.

8. Loke YH, Jayakrishnan A, Mod Razif MRF, Yee KM, Kee PE, Goh BH, Helal Uddin ABM, Lakshminarayanan V, Liew KB. A comprehensive review of challenges in oral drug delivery systems and recent advancements in innovative design strategies. Current Pharmaceutical Design. 2025;31(5):360-76. doi: 10.2174/0113816128338560240923073357.

9. Aulton ME, Taylor KM. Aultons pharmaceutics: the design and manufacture of medicines. In: McConnell EL, Madla CM, Basit AW, editors. Modified-release oral drug delivery. 6th ed. Elsevier; 2021. p. 542-57.

10. Goyal S, Agarwal G, Agarwal S, Karar PK. Oral sustained release tablets: an overview with a special emphasis on matrix tablet. Am J Adv Drug Deliv. 2017;5(2):64-76. doi: 10.21767/2321-547X.1000013.

11. Kanojia N, Singh S, Sharma N. Development of sustained release Eudragit-based matrix tablet of fluvastatin sodium microspheres. Indian J Pharm Sci. 2021;83(6):1229-42. doi: 10.36468/pharmaceutical-sciences.878.

12. Shetty P, Kumar R, Yamunappa SP, Suvarna P, Swamy VN. Design and evaluation of sustained release matrix tablets of etodolac. Asian Jour Pharmac Rese. 2016;6(1):1. doi: 10.5958/2231-5713.2016.00001.5.

13. Mohan V, Mithal A, Joshi SR, Aravind SR, Chowdhury S. Remogliflozin etabonate in the treatment of type 2 diabetes: design, development and place in therapy. Drug Des Dev Ther. 2020 Jun 24;14:2487-501. doi: 10.2147/DDDT.S221093, PMID 32612352.

14. Mohan V, Mithal A, Joshi SR, Aravind SR, Chowdhury S. Remogliflozin etabonate in the treatment of type 2 diabetes: design development and place in therapy. Drug Des Devel Ther. 2020;14:2487-501. doi: 10.2147/DDDT.S221093, PMID 32612352.

15. Grangeia HB, Silva C, Simoes SP, Reis MS. Quality by design in pharmaceutical manufacturing: a systematic review of current status challenges and future perspectives. Eur J Pharm Biopharm. 2019;147:19-37. doi: 10.1016/j.ejpb.2019.12.007, PMID 31862299.

16. Parshuramkar P, Khobragade D, Kashyap P. Comprehension of quality by design in the development of oral solid dosage forms. J Young Pharm. 2023;15(3):406-18. doi: 10.5530/jyp.2023.15.56.

17. Simao J, Chaudhary SA, Ribeiro AJ. Implementation of quality by design (QbD) for development of bilayer tablets. Eur J Pharm Sci. 2023;184:106412. doi: 10.1016/j.ejps.2023.106412, PMID 36828037.

18. Dinde M, Galgatte U, Shaikh F. Development and evaluation of cinnarizine-loaded nanosponges: pharmacodynamic and pharmacokinetic study on Wistar rats. Int J Pharm Sci Rev Res. 2020 Dec 15;65(2):96-105. doi: 10.47583/ijpsrr.2020.v65i02.015.

19. Amsa P, Mathan GK, Magibalan S, Velliyangiri EK, Kalaivani T, Priya S. Formulation and evaluation of gabapentin sustained release matrix tablet using Hibiscus rosa sinensis leaves mucilage as release retardant. J Pharm Res Int. 2021 Dec 16;33(58B):564-72. doi: 10.9734/JPRI/2021/v33i58B34238.

20. Kumari S, Puri A, Dev D, Prasad DN, Monika. Formulation and evaluation of sustained release matrix tablet of metoprolol succinate by using xanthan gum and carbopol. J Drug Deliv Ther. 2019;9(3-s):309-16. doi: 10.22270/jddt.v9i3-s.2844.

21. Nikam BA, Gayke AU. Formulation development and evaluation of an immediate-release tablet of paracetamol and orphenadrine citrate by direct compression method. J Sci Arts. 2022 Sep 30;22(3):735-54. doi: 10.46939/J.Sci.Arts-22.3-b04.

22. Patel P, Dave A, Vasava A, Patel P. Formulation and characterization of sustained release dosage form of a moisture-sensitive drug. Int J Pharm Investig. 2015;5(2):92-100. doi: 10.4103/2230-973x.153385, PMID 25838994.

23. Zhu Y, Yu J, Zhou G, Gu Z, Adu Frimpong M, Deng W. Piperine fast disintegrating tablets comprising sustained release matrix pellets with enhanced bioavailability: formulation in vitro and in vivo evaluation. Pharm Dev Technol. 2020 Feb 11;25(5):617-24. doi: 10.1080/10837450.2020.1725892, PMID 32009511.

24. Jha Sk, Devanna V, Parameshwar K, Reddy MR. Formulation development and evaluation of vildagliptin sustained release tablet. Int J Drug Deliv Technol. 2018;8(4):180-6. doi: 10.25258/ijddt.8.4.5.

25. Gunda RK. Design development and in vitro evaluation of sustained release tablet formulations of olmesartan medoxomil. MOJDDT. 2018 Jun 22;2(3):164-9. doi: 10.15406/mojddt.2018.02.00043.

26. Sandhan S, Sapra K, Mor J. Formulation and evaluation of sustained release matrix tablets of glipizide. Indian J Pharm Biol Res. 2013;1(4):89-94. doi: 10.30750/ijpbr.1.4.16.

27. Zhao Y, Xin T, Ye T, Yang X, Pan W. Solid dispersion in the development of a nimodipine delayed-release tablet formulation. Asian J Pharm Sci. 2014 Feb;9(1):35-41. doi: 10.1016/j.ajps.2013.11.006.

28. Ekenna IC, Abali SO. Comparison of the use of kinetic model plots and DD solver software to evaluate the drug release from griseofulvin tablets. J Drug Deliv Ther. 2022;12(2-S):5-13. doi: 10.22270/jddt.v12i2-S.5402.

29. Gupta SK, Patra S. Development, characterization and pharmacokinetic evaluation of optimized vildagliptin sustained release matrix tablet using box-behnken design. Int J Appl Pharm. 2024;16(1):214-33. doi: 10.22159/ijap.2024v16i1.48052.

30. Gupta SK, Patra S. Development, characterization and pharmacokinetic evaluation of optimized vildagliptin sustained release matrix tablet using box-behnken design. Int J App Pharm. 2024;16(1):214-33. doi: 10.22159/ijap.2024v16i1.48052.

31. Tamilselvi N, Kanagapriya K. Bioequivalence study and bioanalytical method development of remogliflozin etabonate tablets in Wistar rat plasma using RP-HPLC method. Res J Pharm Technol. 2024;17(2):789-94. doi: 10.52711/0974-360X.2024.00122.

32. Ashwin K, Reddy TR. In vivo evaluation of quinapril trilayered matrix tablets. Asian J Pharm Clin Res. 2021;14(7):117-25. doi: 10.22159/ajpcr.2021.v14i7.42002.

33. Inturi R, Raju MD, Basaveswara Rao MV, Inturi S. Pharmacokinetic investigation of remogliflozin in rat plasma samples by high-throughput HPLC-MS-MS. Int J Appl Pharm. 2022;14(6):178-85. doi: 10.22159/ijap.2022v14i6.45700.

34. Aveek Datta, Subhasis Maity, Miltu KR, Ghosh, Kuntal Hazra. Design characterisation and evaluation of sustained release formulation of remogliflozin etabonate. Asian J Pharm Res Dev. 2024;12(6):18-24. doi: 10.22270/ajprd.v12i6.1431.

35. Jivraj II, Martini LG, Thomson CM. An overview of the different excipients useful for the direct compression of tablets. Pharm Sci Technol Today. 2000 Feb;3(2):58-63. doi: 10.1016/S1461-5347(99)00237-0, PMID 10664574.

36. Ceballos A, Cirri M, Maestrelli F, Corti G, Mura P. Influence of formulation and process variables on in vitro release of theophylline from directly-compressed Eudragit matrix tablets. Farmaco. 2005;60(11-12):913-8. doi: 10.1016/j.farmac.2005.07.002, PMID 16129436.

37. Zhao H, Zhao L, Lin X, Shen L. An update on microcrystalline cellulose in direct compression: functionality critical material attributes and co-processed excipients. Carbohydr Polym. 2022 Feb 15;278:118968. doi: 10.1016/j.carbpol.2021.118968, PMID 34973783.

38. Shi C, Zhao H, Fang Y, Shen L, Zhao L. Lactose in tablets: functionality critical material attributes, applications modifications and co-processed excipients. Drug Discov Today. 2023;28(9):103696. doi: 10.1016/j.drudis.2023.103696, PMID 37419210.

39. Lara Garcia RA, Afonso Urich JA, Afonso Urich AI, Jeremic D, Khinast J. Application of lactose co-processed excipients as an alternative for bridging pharmaceutical unit operations: manufacturing an omeprazole tablet prototype via direct compression. Sci Pharm. 2025;93(2):24. doi: 10.3390/scipharm93020024.

40. Ram D, Pankhaniya H. Formulation evaluation and optimization of sustained-release drug delivery system of cisapride tablet. Int J Pharm Pharm Sci. 2021;13(9):56-62. doi: 10.22159/ijpps.2021v13i9.41799.

41. Zhang Y, Law Y, Chakrabarti S. Physical properties and compact analysis of commonly used direct compression binders. AAPS PharmSciTech. 2003 Dec 15;4(4):E62. doi: 10.1208/pt040462, PMID 15198557.

42. Ohwoavworhua FO, Adelakun TA. Some physical characteristics of microcrystalline cellulose obtained from raw cotton of cochlospermum planchonii. Trop J Pharm Res. 2007;4(2):501-7. doi: 10.4314/tjpr.v4i2.14626.

43. Alam S, Bishal A, Bandyopadhyay B. Formulation and evaluation of metformin hydrochloride sustained release matrix tablets. Int J Curr Pharm Res. 2021;13(5):82-8. doi: 10.22159/ijcpr.2021v13i5.1899.

44. Kapur A, O Connor Semmes R, Hussey EK, Dobbins RL, Tao W, Hompesch M. First human dose escalation study with remogliflozin etabonate a selective inhibitor of the sodium glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. BMC Pharmacol Toxicol. 2013 May 13;14:26. doi: 10.1186/2050-6511-14-26, PMID 23668634.

Published

07-01-2026

How to Cite

KHAN, M. A., SOMWANSHI, S. B., VADITAKE, K. T., & KOTADE, K. B. (2026). QBD-DRIVEN DESIGN AND PHARMACOKINETIC PROFILING OF REMOGLIFLOZIN ETABONATE SUSTAINED-RELEASE MATRIX TABLETS FOR DIABETES MANAGEMENT. International Journal of Applied Pharmaceutics, 18(1), 389–400. https://doi.org/10.22159/ijap.2026v18i1.56445

Issue

Vol 18, Issue 1 (Jan-Feb), 2026

Section

Original Article(s)

Copyright (c) 2026 MUSKAN A. KHAN, SACHIN B. SOMWANSHI, KAVERI T. VADITAKE, KIRAN B. KOTADE

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Similar Articles

<< < 135 136 137 138 139 > >> 

You may also start an advanced similarity search for this article.